Literature DB >> 27787446

IMPACT OF VITREORETINAL INTERFACE ARCHITECTURE ON SUCCESSFUL VITREOMACULAR TRACTION RESOLUTION IN EYES SCHEDULED FOR INTRAVITREAL OCRIPLASMIN THERAPY.

Christoph Paul1, Christine Heun, Hans H Müller, Sascha Fauser, Hakan Kaymak, Sara Kazerounian, Walter Sekundo, Stefan Mennel, Carsten H Meyer, Steffen Schmitz-Valckenberg, Michael J Koss, Nicolas Feltgen, Thomas Bertelmann.   

Abstract

PURPOSE: To evaluate the impact of the vitreoretinal interface architecture, in specific the angle between the posterior vitreous cortex and the internal limiting membrane, on vitreomacular traction (VMT) resolution in eyes treated with intravitreally injected ocriplasmin (Jetrea).
METHODS: Retrospective, multicenter cohort study and exploratory data analysis. Spectral domain optical coherence tomography assessments were performed before scheduled ocriplasmin injections. General (age and sex) as well as ocular variables (lens status, presence of epiretinal membrane formations, horizontal diameter of VMT, central retinal thickness, and in particular various prespecified angles between the posterior vitreous cortex and internal limiting membrane) were analyzed to evaluate their impact on successful VMT resolution.
RESULTS: Fifty-nine eyes of 59 patients were included. Univariate analysis of age (odds ratio [OR]: 0.881; 95% CI: [0.812-0.955]; P = 0.0022) and lens status (OR: 11.03; 95% CI: [2.23-54.57]; P = 0.0033) had a significant impact on successful VMT resolution, whereas sex (OR: 0.668; 95% CI: [0.126-2.065]; P = 0.4906), epiretinal membrane formation (OR: 0.581; 95% CI: [0.168-2.006]; P = 0.3903), horizontal diameter of VMT (OR: 0.99930; 95% CI: [0.99825-1.00035]; P = 0.1886), and central retinal thickness (OR: 0.9985; 95% CI: [0.9934-1.00436]; P = 0.56) failed. The angle at 500 μm apart from the fovea centralis, irrespective if measured nasally (OR: 1.135; 95% CI: [1.013-1.272]; P = 0.0289) or temporally (OR: 1.099; 95% CI: [1.001-1.208]; P = 0.0485), showed a significant correlation with VMT resolution.
CONCLUSION: The angle between the posterior vitreous cortex and the internal limiting membrane 500 μm apart from the fovea centralis correlates with VMT resolution and may be a clinically useful marker for selection of patients to be treated with ocriplasmin. This observation needs to be proven in a prospective confirmatory investigation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27787446     DOI: 10.1097/IAE.0000000000001371

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?

Authors:  Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-28       Impact factor: 3.117

2.  The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study.

Authors:  Thomas Bertelmann; Joachim Wachtlin; Stefan Mennel; Michael J Koss; Mathias M Maier; Ricarda G Schumann; Sara Kazerounian; Hanna Daniel; Steffen Schmitz-Valckenberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-07       Impact factor: 3.117

3.  Letter of response to "Comment re: Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?"

Authors:  C Paul; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-22       Impact factor: 3.117

Review 4.  Ocriplasmin for symptomatic vitreomacular adhesion.

Authors:  James E Neffendorf; Varo Kirthi; Edward Pringle; Timothy L Jackson
Journal:  Cochrane Database Syst Rev       Date:  2017-10-17

5.  Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?

Authors:  Kleanthis Manousaridis; Silvia Peter-Reichart; Stefan Mennel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-05       Impact factor: 3.117

6.  Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.

Authors:  Christoph Paul; Hans-Helge Müller; Thomas Raber; Thomas Bertelmann
Journal:  PLoS One       Date:  2022-07-25       Impact factor: 3.752

7.  Anatomical and functional outcomes of pneumatic vitreolysis for treatment of vitreomacular traction with and without macular holes.

Authors:  Carmen Baumann; Francesco Sabatino; Yalin Zheng; Navid Johannigmann-Malek; Mathias Maier; Stephen B Kaye; Niall Patton
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-05       Impact factor: 3.535

8.  Vitrectomy in full thickness macular holes on top of a pigment epithelial detachment in age-related macular degeneration (AMD). Surgical consideration and review of the literature.

Authors:  Paula S Meyer; Marc T Kammann; Carsten H Meyer
Journal:  Am J Ophthalmol Case Rep       Date:  2021-07-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.